Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 8/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24650729 | 0.94 | MAPT (0.45) | ADRA1AMAPTDRD2DRD3CYP1A2 | |
| SCHEMBL24650727 | 0.88 | PDE4A (0.38) | ADRA1A | |
| SCHEMBL24650381 | 0.87 | ADRA1A (0.41) | ADRA1AMAPTCYP1A2 | |
| SCHEMBL24650732 | 0.86 | ADRA1A (0.41) | ADRA1AMAPTDRD2DRD3 | |
| SCHEMBL24650403 | 0.86 | LMNA (0.39) | ADRA1ADRD2DRD3 | |
| SCHEMBL24650734 | 0.84 | ADRA1A (0.36) | ADRA1AMAPTDRD2DRD3CYP1A2 | |
| SCHEMBL24651148 | 0.84 | ADRA1A (0.44) | ADRA1ADRD2DRD3 | |
| SCHEMBL24650450 | 0.84 | DRD2 (0.47) | ADRA1AMAPTDRD2DRD3CYP1A2 | |
| SCHEMBL24651158 | 0.82 | ADRA1A (0.44) | ADRA1AMAPTCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL24651146 | 0.82 | ADRA1A (0.58) | ADRA1AMAPTDRD2DRD3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022238507-A1 | THERAPEUTIC AMINOINDANE COMPOUNDS AND COMPOSITIONS | AWAKN LS EUROPE HOLDINGS LIMITED (IE) | 2022-11-17 | — | — | WO | disclosed |